October 2024 FAQs
- Update: Does the literature support the use of doxycycline for post-exposure prophylaxis against sexually transmitted infections?
- Update: What is the role for commercially available fecal microbiota transplantation products in managing recurrent Clostridioides difficile infection?
- Are there data to support dose intensification of golimumab for moderate to severe inflammatory bowel disease (e.g., 100 mg every 2 weeks)?